Blue Jet Healthcare Q1 FY26: Revenue 354.8 Cr

Key dates investors are tracking

Blue Jet Healthcare Ltd. has multiple events and reference points in focus for shareholders. The company’s board meeting to consider audited financial results is scheduled for August 03, 2026. On the same day, an investor earnings conference call is scheduled for 5:30 PM IST.

The company has also flagged an upcoming earnings date of 25th May, 2026. Separately, the quick details section lists the results date as August 03, 2026 for Q1 FY 2026-2027. The dataset also notes that there is no quarterly earnings forecast data available for the stock.

Board meeting and investor call: who will be on the line

The investor call on August 03, 2026 is set to include Managing Director Shiven Arora, COO V.K. Singh, CFO Ganesh Karuppannan, and Deputy CFO Sanjay Sinha. The stated purpose is linked to the scheduled board meeting where audited financial results are to be considered.

These events matter because they are typically where management discusses performance drivers, margins, working capital, and business priorities, alongside the statutory numbers. Here, the company has already shared several operational and margin datapoints across quarters that investors will likely use as reference.

FY26 audited results: revenue and profit for the year

Blue Jet Healthcare Limited released its audited standalone financial results for the financial year ended March 31, 2026. As reported, revenue from operations stood at ₹947.32 crore (₹9,473.21 million). Profit for the year was ₹247.82 crore (₹2,478.16 million).

The company also said the Board has proposed a final dividend of ₹1.20 per share, subject to shareholder approval. In the same information set, the company is shown as having declared a dividend of ₹1.20 on 19 Sep, 2025.

Quarterly context: “previous quarter” reference points

The quick details provided alongside the results date include several “previous quarter” metrics. Previous quarter revenue is listed as ₹234.7 crore, and previous quarter PAT is ₹64.3 crore. Previous quarter EBITDA margin is stated at 30.4%.

Other market-facing reference points in the same snapshot include CMP of ₹580.3 and a market capitalisation figure of ₹10,980.82 crore.

Q1 FY26 performance: revenue, EBITDA, PAT and margins

For Q1 FY26, revenue from operations is reported at INR 3,548 million, which normalises to ₹354.8 crore. The update states this was up 4.2% quarter-on-quarter compared to INR 3,404 million, and up 117.8% year-on-year compared to INR 1,629 million.

EBITDA for the quarter is reported at INR 1,210 million, which is ₹121.0 crore. This is described as down 13.6% quarter-on-quarter (from INR 1,400 million) and up 173.3% year-on-year (from INR 443 million). EBITDA margin for the quarter is stated at 34.1%, versus 41.4% in Q4FY25 and 27.2% in Q1FY25.

Profit after tax (PAT) for the quarter is reported at INR 912 million, which is ₹91.2 crore. The update states PAT declined 17.2% sequentially compared to INR 1,101 million, and rose 141.3% year-on-year compared to INR 378 million. PAT margin is stated at 25.7%.

What the company attributed margin movement to

The update links the quarter-on-quarter decline in margins to production phasing, inventory normalisation and product mix. It also highlights a gross margin of about 48.4% to 48.5% in Q1 FY26, compared with 55% in the prior quarter.

The gross margin decline is attributed to a drawdown of finished goods inventory, which released previously inventorized overhead costs into the profit and loss account. Managing Director Shiven Arora is cited as indicating gross margin is anticipated to stabilise around 53% after factoring in the one-time inventory effect.

Q3 FY26 update: sharp YoY drop in revenue and EBITDA

A separate quarterly datapoint in the provided information states that Blue Jet Healthcare’s Q3 FY26 revenue dropped 40% year-on-year to ₹192.4 crore from ₹318.4 crore. EBITDA is stated to have declined 62% to about ₹46.2 crore.

The reason cited for this Q3 movement is channel destocking and supply chain realignment. The company also indicated that it would hold a Board Meeting on February 13, 2026 to approve unaudited standalone financial results for Q3 and nine months ended December 31, 2025.

Profitability table and Q1 results table: figures as presented

The provided quarterly table includes Total Income, EBIT, PAT, and margin metrics across MAR 2026, DEC 2025, SEPT 2025, JUN 2025, and MAR 2025. It lists PAT for MAR 2026 at 64.34, for DEC 2025 at 40.17, for SEPT 2025 at 52.14, for JUN 2025 at 91.17, and for MAR 2025 at 110.10, with corresponding growth percentages.

A separate “Quarterly - Blue Jet Healthcare Q1 Results” table (noted as “All figures in crores except per share values”) lists Total Revenue of 354.76 for Jun 25 and 234.67 for Mar 26, along with Net Income of 91.17 and 64.34, respectively. It also provides Diluted Normalized EPS of 5.26 (Jun 25) and 3.71 (Mar 26).

Snapshot table: key numbers mentioned

EPS and forecasts: what is and is not available

The dataset lists the reported EPS for Blue Jet Healthcare Ltd. as 14.29, while estimated EPS is shown as “--”. It also explicitly states that no quarterly earnings forecast data is available for the stock.

This means investors relying on consensus estimates will need to focus more on the company’s disclosed quarterly trajectory, margin drivers, and management commentary from scheduled calls and filings.

Conclusion

Blue Jet Healthcare’s disclosed updates combine audited FY26 results, quarter-level operating and margin indicators, and a forward calendar that includes the August 03, 2026 board meeting and investor call. The next stated earnings date is 25th May, 2026, while shareholders will also watch for updates related to the proposed ₹1.20 final dividend and management commentary on gross margin normalisation.